Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Xisomab 3G3 - Aronora

Drug Profile

Xisomab 3G3 - Aronora

Alternative Names: AB 022; AB 023; Anti-factor XI Monoclonal Antibody Xisomab 3G3; Anti-FXI Antibody Xisomab 3G3; Mab 14E11 - Aronora; XISOMAB; Xisomab3G3

Latest Information Update: 28 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Oregon Health & Science University
  • Developer Aronora
  • Class Anti-infectives; Antiseptics; Antithrombotics; Cardiovascular therapies; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Factor XI inhibitors; Factor XII inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Thrombosis
  • No development reported Cardiovascular disorders; Neurological disorders; Sepsis

Most Recent Events

  • 28 Dec 2022 No recent reports of development identified for research development in Neurological-disorders in USA (Parenteral)
  • 10 Dec 2022 Efficacy and adverse events data from a phase II trial in Thrombosis (Prevention) presented at the at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
  • 05 Nov 2021 Aronora in collaboration with Oregon Health and Science University terminates a phase II trial for Thrombosis (Prevention) in USA (IV), due to an IP manufacturing issue (NCT04465760)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top